OncoMatch/Clinical Trials/NCT06835049

Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

Is NCT06835049 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Doxorubicin and Ifosfamide for sarcoma,soft tissue.

Phase 2RecruitingSwiss Cancer InstituteNCT06835049Data as of May 2026

Treatment: Doxorubicin · Ifosfamide · Dacarbazine — Soft tissue sarcomas (STSs) are rare cancers with a 5-year survival rate of 60%, and there is no standard treatment for high-risk extremity and trunk STSs (eSTS). A phase III trial suggests that adding moderate regional hyperthermia (HT) to anthracycline-based chemotherapy, followed by surgery and radiotherapy (RT), can improve 10-year overall survival by 10%. This trial aims to optimize treatment by combining the most effective regimens from chemotherapy, HT, RT, and surgery, and will evaluate the feasibility of this new total neoadjuvant treatment (TNT) approach.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Disease stage

Excluded: Stage IV

Measurable disease per RECIST v1.1.

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiation therapy

Any previous radiotherapy (RT) or systemic therapy for the present tumor.

Cannot have received: systemic therapy

Any previous radiotherapy (RT) or systemic therapy for the present tumor.

Cannot have received: anthracycline (doxorubicin, daunorubicin, epirubicin, idarubicin, anthracenediones)

Exception: maximum cumulative doses (450 mg/m² doxorubicin or equivalent 900 mg/m² epirubicin)

Previous treatment with maximum cumulative doses (450 mg/m² doxorubicin or equivalent 900 mg/m² epirubicin) of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones.

Lab requirements

Blood counts

Kidney function

Liver function

Cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify